wetenschapsdag 2023 | 41 Sessie 1c: We Zullen Doorgaan x2 Auteurs B. ten Haaft, S. Franssen, R.W.J. van Dorst, M. Rousian, G. Pilz da Cunha, R.F. de Wilde, J.I. Erdmann, B. Groot Koerkamp, J. Hagendoorn, R. Swijnenburg Abstract titel Robotic versus Open Hepatic Arterial Infusion Pump Placement for Unresectable Intrahepatic Cholangiocarcinoma: Results From a Prospective Multicenter Phase II Trial Background Hepatic arterial infusion pump (HAIP) chemotherapy is an effective treatment for patients with unresectable intrahepatic cholangiocarcinoma (iCCA). HAIP chemotherapy requires a catheter inserted in the gastroduodenal artery and a subcutaneous pump. The catheter can be placed with an open or robotic approach. This study aims to compare perioperative outcomes of robotic versus open HAIP placement in patients with unresectable iCCA. Methods We analyzed patients with unresectable iCCA included in the PUMP-II trial from January 2020 to September 2022 undergoing robotic or open HAIP placement at Amsterdam UMC, Erasmus MC, and UMC Utrecht. The primary outcome was time to functional recovery (TTFR). Results In total, 22 robotic and 28 open HAIP placements were performed. The median TTFR was 2 days after robotic versus 5 days after open HAIP placement (P<0.001). One patient (4.5%) in the robotic group underwent a conversion to open because of a large bulky tumor leaning on the hilum immobilizing the liver. Postoperative complications were similar; 36% (8/22) after robotic versus 39% (11/28) after open placement (P=1.000). The median length of hospital stay was shorter in the robotic group; 3 versus 5 days (P<0.001). All 22 robotic patients initiated HAIP chemotherapy post-surgery, this was 93% (26/28) in the open group (P=0.497). The median time to start HAIP chemotherapy was 14 versus 18 days (P=0.153), respectively. Conclusion Robotic HAIP placement in patients with unresectable iCCA is a safe and effective procedure and is associated with a significantly shorter TTFR and hospital stay than open HAIP placement.
RkJQdWJsaXNoZXIy MTk4NDMw